University of Texas Health Science Center at Houston

Major clinical trial to test Pfizer-BioNTech COVID-19 vaccine opens for enrollment at UTHealth in Houston

Newswise — A large national clinical trial to evaluate the Pfizer-BioNTech COVID-19 vaccine for safety and efficacy in pregnant women is now open for enrollment at The University of Texas Health Science Center at Houston (UTHealth).

“Pregnant women who are infected with COVID-19 are five times more likely to have severe illness, be admitted to a hospital, or have preterm delivery. But because we have limited data from pregnant women who are not on placebo-controlled trials or have self-reported after vaccination, the best way to learn of efficacy, differences in side effects, or possible impact on fetal development is through a randomized, double-blinded, placebo-controlled trial,” said Houston site lead investigator Sandra Hurtado, MD, an assistant professor of OB-GYN with McGovern Medical School at UTHealth.

For the Phase II/III study, researchers across the country are enrolling 4,000 healthy women over the age of 18 who are between 27 and 34 weeks pregnant. The trial is randomized and placebo-controlled and sites are allowed to recruit competitively until all slots are filled. It is also investigator-blinded, so that only the nurse who gives the shot, who is not part of the research team, knows whether the patient received the vaccine or placebo. The Houston site is in the UTHealth Women’s Research Program – Memorial City.

“UTHealth Houston is a very diverse community at the forefront of clinical and biological research, so it’s important for us to participate in trials that can make a difference for our nation and world,” Hurtado said. “With our diversity in ethnicities and culture, we can integrate a different population base in the trial.”

Women who are part of the UTHealth site trial will be required to deliver their baby at Memorial Hermann Memorial City so that the researchers can collect and test the cord blood to see if antibodies that may have developed in the mother have transferred to the child. After delivery, women will be told whether or not they received the vaccine and any who were in the placebo arm will be able to receive it. Patients who received the vaccine and their infants will be followed for six months after delivery.

“Women who participate understand that they may or may not get the drug, but they have an interest in being able to advance medicine and science,” Hurtado said.

Joining Hurtado, who is in the Department of Obstetrics, Gynecology and Reproductive Services, on the study are Ebony Beaudoin, MD, associate professor in the Department of Pediatrics at McGovern Medical School; Lori Wink, NP, with UT Physicians Women’s Center-Bellaire and UT Physicians Women’s Center II-Memorial City; and Joanne Veloz Jacinto, RN, study coordinator with the UTHealth Women’s Research Program – Memorial City. UT Physicians is the clinical practice of McGovern Medical School.

For more information about the trial, call 713-486-6640 or visit the website.

For media inquiries, call 713-500-3030

Filters close

Showing results

110 of 5639
access_time Embargo lifts in 2 days
Embargo will expire: 20-May-2021 10:00 AM EDT Released to reporters: 14-May-2021 2:40 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 20-May-2021 10:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 14-May-2021 11:25 AM EDT
Access to overdose-reversing drugs declined during pandemic, researchers find
Beth Israel Lahey Health

In a new study, clinician-researchers at Beth Israel Deaconess Medical Center (BIDMC) analyzed naloxone prescription trends during the COVID-19 pandemic in the United States and compared them to trends in opioid prescriptions and to overall prescriptions.

Released: 14-May-2021 11:00 AM EDT
No Excuses: Stop Procrastinating on These Key Health Checks
Michigan Medicine - University of Michigan

A quick guide to the most-valuable preventive care that adults need to get scheduled, to catch up on what they may have missed during the height of the pandemic, and to address issues that the pandemic might have worsened.

Released: 13-May-2021 7:05 PM EDT
FLCCC Statement on the Irregular Actions of Public Health Agencies & the Disinformation Campaign Against Ivermectin
Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)

FLCCC Alliance calls for whistleblower to step forward from within WHO, the FDA, the NIH, Merck, or Unitaid to counter this misrepresentation

Newswise: shutterstock_1724336896.jpg
Released: 13-May-2021 12:55 PM EDT
Kreuter receives $1.9 million in grants to increase vaccinations in St. Louis
Washington University in St. Louis

Matthew Kreuter, the Kahn Family Professor of Public Health at the Brown School, has received $1.9 million in grants to help increase COVID-19 vaccinations among Blacks in St. Louis City and County.

Released: 13-May-2021 11:35 AM EDT
COVID-19 mRNA Vaccines are Immunogenic in Pregnant and Lactating Women, Including Against Viral Variants
Beth Israel Deaconess Medical Center

In a new study from Beth Israel Deaconess Medical Center researchers evaluated the immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women who received either the Pfizer or Moderna COVID-19 vaccines. They found that both vaccines triggered immune responses in pregnant and lactating women.

Released: 13-May-2021 10:30 AM EDT
Pandemic stigma: Foreigners, doctors wrongly targeted for COVID-19 spread in India
Monash University

The Indian public blamed foreigners, minority groups and doctors for the rapid spread of COVID-19 across the country during the first wave, due to misinformation, rumour and long-held discriminatory beliefs, according to an international study led by Monash University.

Released: 13-May-2021 9:15 AM EDT
28 Community Programs Receive Grants Through Penn Medicine CAREs Program
Perelman School of Medicine at the University of Pennsylvania

Penn Medicine CAREs awarded grants to 28 projects, many of which aim to fill vast needs in the community created by the COVID-19 pandemic, while others seek to improve diversity, equity, and inclusion.

Showing results

110 of 5639